Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Globe Newswire•31/08/2026•07:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.